Arecor Therapeutics PLC Arecor Publishes Data for AT278 in Diabetes Care
January 30 2023 - 2:00AM
RNS Non-Regulatory
TIDMAREC
Arecor Therapeutics PLC
30 January 2023
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
ARECOR ANNOUNCES PUBLICATION OF PHASE I DATA FOR AT278 IN
DIABETES CARE
- Ultra-concentrated, ultra-rapid acting insulin AT278, a
promising candidate in the pursuit of next generation insulins to
simplify and improve glycemic control
Cambridge, UK, 30 January 2023: Arecor Therapeutics plc, a
globally focused biopharmaceutical company advancing today's
therapies to enable healthier lives, today announces that the
American Diabetes Association journal, Diabetes Care, has published
data from the Company's Phase I clinical trial of AT278, its
ultra-concentrated (500 U/mL), ultra-rapid acting insulin product
candidate.
The manuscript, titled 'Pharmacokinetics and Pharmacodynamics of
a Novel U500 Insulin Aspart Formulation: A Randomized,
Double-Blind, Crossover Study in People with Type 1 Diabetes', is
now available online.
In the Phase I clinical study in people with Type I diabetes,
AT278 (500 U/mL) clearly demonstrated faster insulin absorption
with an accelerated pharmacokinetic (PK) and pharmacodynamic (PD)
profile compared to gold-standard insulin NovoRapid(R) (100 U/mL)
despite a 5-fold increase in concentration.
AT278 is an ultra-concentrated (500 U/mL) novel formulation of
insulin that has been designed to accelerate the absorption of
insulin post injection, even when delivered at a high
concentration, and hence via a lower injection volume. Currently,
there are no concentrated (>200 U/mL) rapid acting insulin
products on the market, and therefore, AT278 has the potential to
be the first such product available to patients. It has the
potential to enable more effective management of blood glucose
levels to the increasing number of people with diabetes with high
daily insulin requirements (>200 units/day) whilst maintaining
the convenience and compliance benefits of being able to deliver
these high insulin doses in a lower injection volume via a single
injection. In addition, a truly rapid acting concentrated insulin
is also a critical step towards the advancement and miniaturisation
of the next generation of insulin delivery devices.
Dr Eva Svehlikova, first author of the study, said: "Publication
of these data in a peer-reviewed journal supports the
representation of AT278 as a promising candidate in the pursuit of
next generation insulin analogs designed to improve postprandial
glycemic control with its superior PK/PD profile as well as
reducing the injection volume and/or number of daily injections for
people with diabetes who have high daily insulin needs."
Sarah Howell, Chief Executive Officer of Arecor, said: "
Publication of the AT278 clinical trial in this prestigious journal
highlights the significance of this clinical data and the need for
our next generation insulins to bring improved treatment options to
people living with diabetes to simplify and improve their blood
glucose management. As a potential market disrupter, AT278 has the
potential to become the gold standard insulin for the growing
population of people with diabetes with high daily insulin needs as
well as a critical enabler in the development of next generation
miniaturised insulin delivery systems. With approximately 537
million people living with diabetes worldwide, of which
approximately 56 million are insulin users, there has never been a
greater need for improved treatment options."
AT278 is also currently being investigated in a second Phase I
trial in patients with Type 2 diabetes, to further explore the
product's potential to disrupt the market as the first
concentrated, yet rapid acting, insulin. The study initiated
earlier this month and is expected to complete within Q4 2023.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD
and Broker)
Freddy Crossley, Emma Earl (Corporate Tel: +44 (0) 20 7886 2500
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
group transforming patient care by bringing innovative medicines to
market through the enhancement of existing therapeutic products. By
applying our innovative proprietary formulation technology
platform, Arestat(TM), we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat(TM) platform is supported by an extensive patent
portfolio.
For further details please see our website, www.arecor.com
About Diabetes Care
Diabetes Care is a journal for the health care practitioner that
is intended to increase knowledge, stimulate research, and promote
better management of people with diabetes. For further details
please see the website, https://care.diabetesjournals.org/
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAWPUQWGUPWUQU
(END) Dow Jones Newswires
January 30, 2023 02:00 ET (07:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jul 2023 to Jul 2024